Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE:MTEC), a leading business technology company in the cannabis space, is pleased to announce that its premiere cannabis education platform, Cannvas.me will be offered through a physical device in medical and related clinics. Patients and medical professionals will have access to a low cost, application specific, hand held device to learn about the benefits of health and wellness through cannabis and to access information specific to their needs.

“Through discussions with medical professionals, the need for education at the point of treatment was clearly evident,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “Our solution is to have a physical device specific to medical cannabis education and information in medical and related clinics. Our goal is to quickly expand our offering to every clinic across Canada and friendly jurisdictions around the world. Throughout the development of Cannvas.me this has been taken into consideration while rolling out the landscape of integration with potential clinic partners. With the Cannvas.me platform launch quickly approaching, we are in a position to accelerate those conversations and convert them into integrated educational delivery partners.”


Through widespread medical clinic integration, medical patients will be able to access the Cannvas.me education platform at the source of their treatment: medical and related clinics. Access to trusted information is important for both the patient and the prescribing medical professional. Due to the lack of available information, medical professionals have been reluctant to prescribe cannabis in its many forms. By providing information at the source of treatment, it will give the patient peace of mind by looking at all alternatives and doctors the confidence to write the suitable prescriptions for the specific ailments.

Cannvas is currently in the final stages of partnership integration protocols and revenue share guidelines, which would be utilized with our potential partners. Cannvas has set aggressive expansion targets which we feel are achievable through current discussions with existing networks worldwide.

Cannvas also announces that it has issued an aggregate of 3,500,000 common shares (the “Shares”) of the Company at a deemed value of $0.35 per Share to Shawn Moniz, CEO and a director of the Company, and Steve Loutskou, COO and a director of the Company, pursuant to the achievement of certain milestones and in accordance with their respective consulting agreements.

About Cannvas.me

Cannvas.me is an innovative and unbiased online health sciences educational platform where patients can take an active role in defining the path of control of their health and wellness through the use of cannabis. It is a scalable and comprehensive solution for the global cannabis community offering interactive tools and physician-backed content. It takes an innovative approach to place cannabis education at the forefront by bringing design, creativity, data aggregation and global connectivity to new heights. Through subsidiaries Cannvas Creative, Cannvas Data and Cannvas Connect; Cannvas.me will feature innovative tools such as educational learning modules in its Cannvas University, an interactive Cannvas Strain Matcher that educates audiences with specific ailments, and Cannvas Culinary, for those wishing to learn about the culinary approach to treatments.

About Cannvas MedTech Inc.

Cannvas MedTech is a leading business technology company within the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

Click here to connect with Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE:MTEC) for an Investor Presentation. 

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less